Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 9Breast Neoplasms 9Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5Squamous Cell Carcinoma of Head and Neck 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms, Unknown Primary 2Neoplasms 2NSCLC 2Melanoma 2Esophageal Neoplasms 2Adenocarcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1

Interventions

pembrolizumab 162Carboplatin 144Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 38Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × CP protocol × Clear all
NCT07610525 2026-05-28

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
200 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03168880 2025-04-09

TNBC

Tata Memorial Hospital

Phase 3 Active not recruiting
720 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡